Search Results

You are looking at 1 - 10 of 46 items for :

Clear All
Full access

Randall W. Burt, James S. Barthel, Kelli Bullard Dunn, Donald S. David, Ernesto Drelichman, James M. Ford, Francis M. Giardiello, Stephen B. Gruber, Amy L. Halverson, Stanley R. Hamilton, Mohammad K. Ismail, Kory Jasperson, Audrey J. Lazenby, Patrick M. Lynch, Edward W. Martin Jr., Robert J. Mayer, Reid M. Ness, Dawn Provenzale, M. Sambasiva Rao, Moshe Shike, Gideon Steinbach, Jonathan P. Terdiman and David Weinberg

, prospective, triple-blinded trial that also assessed a second-generation combination test: SDT-2 ( APC, K-ras , and vimentin methylation). 40 A total of 3764 average-risk healthy adults underwent screening colonoscopy, Hemoccult, Hemoccult Sensa, SDT-1, and

Full access

Brandon A. Dyer, Dmitriy Zamarin, Ramez N. Eskandar and Jyoti M. Mayadev

between a T cell and an antigen-presenting cell (APC). T-cell activation requires multiple ligand:receptor interactions, including the APC major histocompatibility complexes (MHCI):T-cell receptor (TCR), and B7.1, 2 (ie, CD80/CD86):CD28. T-cell activation

Full access

Saby George, Roberto Pili, Michael A. Carducci and Jenny J. Kim

of antigen-presenting cell/tumor cell and T-cell receptor interaction in T-cell activation. Abbreviation: APC, antigen-presenting cell; CTLA, cytotoxic T-lymphocyte antigen; PD1, programmed death 1. From Drake CG. Prostate cancer as a model for

Full access

Samir Gupta, Dawn Provenzale, Scott E. Regenbogen, Heather Hampel, Thomas P. Slavin Jr, Michael J. Hall, Xavier Llor, Daniel C. Chung, Dennis J. Ahnen, Travis Bray, Gregory Cooper, Dayna S. Early, James M. Ford, Francis M. Giardiello, William Grady, Amy L. Halverson, Stanley R. Hamilton, Jason B. Klapman, David W. Larson, Audrey J. Lazenby, Patrick M. Lynch, Arnold J. Markowitz, Robert J. Mayer, Reid M. Ness, Niloy Jewel Samadder, Moshe Shike, Shajanpeter Sugandha, Jennifer M. Weiss, Mary A. Dwyer and Ndiya Ogba

polyposis (specific to APC, MUTYH, POLE , and POLD1 ) Family history does not meet criteria for established testing guidelines but there is suspicion of hereditary cancer, and an appropriate panel is available Family history is limited or unknown but

Full access

Patrick M. Lynch

/print certificate. Release date: December 16, 2013; Expiration date: December 16, 2014 Learning Objectives Upon completion of this activity, participants will be able to: Explain factors to consider when deciding whether to perform APC testing for

Full access

Dung T. Le and Elizabeth M. Jaffee

-resistant prostate cancer (mCRPC) based on an improvement in overall survival (OS) from 21.7 to 25.8 months over placebo (hazard ratio [HR], 0.78; P =.03). 1 The product is generated using patient’s cells as the source of the antigen-presenting cells (APCs

Full access

Patrick M. Lynch

. Molecular analysis of the APC gene in 105 Dutch kindreds with familial adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and southern analysis . Hum Mutat 1997 ; 9 : 7 – 16 . 16. Meuller J Kantor-Smoler G Nygren AOH

Full access

Minhhuyen T. Nguyen and David S. Weinberg

to chromosomal imbalance (aneuploidy) and a high frequency of loss of heterozygosity (LOH). In 1990, Vogelstein et al 16 first proposed a specific sequence of mutations in the APC, Kras , and p53 genes in colon carcinogenesis. However, multiple

Full access

Ravi A. Madan, Thomas Schwaab and James L. Gulley

widely available for randomized multicenter trials because of the intensive resource requirements. Another option, represented by sipuleucel-T, is to use antigen-presenting cells (APCs) to initiate a diverse, lasting, tumor-specific immune response. 2 In

Full access

Thomas B. Nealis, Kay Washington and Rajesh N. Keswani

technique is chosen. Ablation Techniques Argon Plasma Coagulation: Argon plasma coagulation (APC) is a thermal cautery device that uses a constant flow of ionized argon gas to transmit high-frequency current to the tissue to cause superficial (2